These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20310025)

  • 1. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics.
    Singh SK; Afonina N; Awwad M; Bechtold-Peters K; Blue JT; Chou D; Cromwell M; Krause HJ; Mahler HC; Meyer BK; Narhi L; Nesta DP; Spitznagel T
    J Pharm Sci; 2010 Aug; 99(8):3302-21. PubMed ID: 20310025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of subvisible particles in therapeutic proteins.
    Singh SK; Toler MR
    Methods Mol Biol; 2012; 899():379-401. PubMed ID: 22735966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in Flow-Imaging Microscopy Measurements and Considerations for Biopharmaceutical Development.
    Rauk AP; Griffiths KL; Gossage MD; Weiss WF
    J Pharm Sci; 2016 Nov; 105(11):3296-3303. PubMed ID: 27663382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
    Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L
    J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silicone-oil-based subvisible particles: their detection, interactions, and regulation in prefilled container closure systems for biopharmaceuticals.
    Felsovalyi F; Janvier S; Jouffray S; Soukiassian H; Mangiagalli P
    J Pharm Sci; 2012 Dec; 101(12):4569-83. PubMed ID: 23023774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Particles in therapeutic protein formulations, Part 1: overview of analytical methods.
    Zölls S; Tantipolphan R; Wiggenhorn M; Winter G; Jiskoot W; Friess W; Hawe A
    J Pharm Sci; 2012 Mar; 101(3):914-35. PubMed ID: 22161573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation.
    Wuchner K; Büchler J; Spycher R; Dalmonte P; Volkin DB
    J Pharm Sci; 2010 Aug; 99(8):3343-61. PubMed ID: 20229596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator.
    Patel AR; Lau D; Liu J
    Anal Chem; 2012 Aug; 84(15):6833-40. PubMed ID: 22794526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation.
    Carpenter J; Cherney B; Lubinecki A; Ma S; Marszal E; Mire-Sluis A; Nikolai T; Novak J; Ragheb J; Simak J
    Biologicals; 2010 Sep; 38(5):602-11. PubMed ID: 20702108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products.
    Cash PW; Narwal R; Levitskaya SV; Krause S; Murphy D; Mazaheri M
    PDA J Pharm Sci Technol; 2016; 70(2):134-42. PubMed ID: 26797974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging.
    Sharma DK; Oma P; Pollo MJ; Sukumar M
    J Pharm Sci; 2010 Jun; 99(6):2628-42. PubMed ID: 20049937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of flow cytometry for the detection of subvisible particles in therapeutic protein formulations.
    Mach H; Bhambhani A; Meyer BK; Burek S; Davis H; Blue JT; Evans RK
    J Pharm Sci; 2011 May; 100(5):1671-8. PubMed ID: 21374606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein particles: what we know and what we do not know.
    Ripple DC; Dimitrova MN
    J Pharm Sci; 2012 Oct; 101(10):3568-79. PubMed ID: 22736521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Issues and challenges of subvisible and submicron particulate analysis in protein solutions.
    Scherer TM; Leung S; Owyang L; Shire SJ
    AAPS J; 2012 Jun; 14(2):236-43. PubMed ID: 22391789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles--Differential Centrifugation and FACS.
    Boll B; Folzer E; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV
    Pharm Res; 2015 Dec; 32(12):3952-64. PubMed ID: 26195006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy.
    Narhi LO; Corvari V; Ripple DC; Afonina N; Cecchini I; Defelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Spitznagel TM; Weiskopf A; Wuchner K
    J Pharm Sci; 2015 Jun; 104(6):1899-1908. PubMed ID: 25832583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Industry perspective on the medical risk of visible particles in injectable drug products.
    Bukofzer S; Ayres J; Chavez A; Devera M; Miller J; Ross D; Shabushnig J; Vargo S; Watson H; Watson R
    PDA J Pharm Sci Technol; 2015; 69(1):123-39. PubMed ID: 25691720
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of Proteinaceous Particles in Monoclonal Antibody Drug Products Using Mass Spectrometry.
    Xu X; Hu Q; Liu D; Qiu H; Shameem M; Li N
    J Pharm Sci; 2021 Oct; 110(10):3403-3409. PubMed ID: 34139261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.